Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK is the Company's first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit , and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day.
匹茲堡，2024年11月06日（環球新聞社） -- krystal biotech股份有限公司（"公司"）（納斯達克：KRYS），一家商業階段的生物技術公司，今天宣佈公司將參加於2024年11月12日在波士頓舉行的古根海姆證券醫療創新大會。首席執行官兼主席Krish S. Krishnan將參加於下午1:30 Et舉行的爐邊聊天，並全天舉行投資者會議。
A webcast of the presentation will be available here beginning at 1:30 pm ET on Tuesday, November 12, 2024 and will be posted on the Investors section of the Company's website.
演示文稿的網絡直播將於2024年9月10日ET下午12:30開始，將在該公司的投資者部分發布。 here 從2024年11月12日星期二下午1:30 Et開始，將在公司的投資者部分發布。 網站.
About Krystal Biotech, Inc.
關於krystal biotech，公司
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK is the Company's first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit , and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
Krystal Biotech公司（納斯達克：KRYS）是一家專注於發現、開發和商業化用於治療高度未滿足醫療需求疾病的基因藥物的商業階段生物技術公司。VYJUVEk是公司的首個商業產品，也是首個可以重複使用的基因治療產品，也是美國食品藥品監督管理局批准用於治療肌萎縮性表皮溢膿性鬆解症的第一藥物。該公司正在快速推進一個強大的臨床前和臨床試驗管線，研發調查用於呼吸系統、腫瘤學、皮膚科、眼科醫療和美容領域的基因藥物。Krystal Biotech總部位於賓夕法尼亞州匹茲堡。欲了解更多信息，請訪問 ，並在（原twitter）上關注@KrystalBiotech領英 和 X，並在（原twitter）上關注@KrystalBiotech
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
spaquette@krystalbio.com
聯繫方式
投資者和媒體：
Stéphane Paquette
krystal biotech
spaquette@krystalbio.com
譯文內容由第三人軟體翻譯。
